These data suggest that ipragliflozin might inhibit NASH development in the liver, reinforcing the activity of the key ROS-scavenging antioxidant enzymes SOD2 and CAT directly or indirectly. The gene discussed is SOD2; the disease is metabolic dysfunction-associated steatohepatitis.